Sangamo BioSciences

Last updated: April 15, 2024

Sandy Macrae, CEO
Sandy Macrae, CEO
Country: USA | Funding: $546.1M (+)

Website: http://www.sangamo.com

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.